Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment
NCT07460206
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
108
Enrollment
OTHER
Sponsor class
Conditions
ccRCC
Interventions
DRUG:
Pembrolizumab 200 mg Q3W
DRUG:
Lenvatinib 20mg QD
Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica